Logo image of TMCI

TREACE MEDICAL CONCEPTS INC (TMCI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TMCI - US89455T1097 - Common Stock

2.46 USD
+0.04 (+1.65%)
Last: 12/29/2025, 8:22:15 PM
2.49 USD
+0.03 (+1.22%)
After Hours: 12/29/2025, 8:22:15 PM
Fundamental Rating

3

Overall TMCI gets a fundamental rating of 3 out of 10. We evaluated TMCI against 186 industry peers in the Health Care Equipment & Supplies industry. TMCI may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, TMCI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TMCI had negative earnings in the past year.
In the past year TMCI has reported a negative cash flow from operations.
In the past 5 years TMCI always reported negative net income.
In the past 5 years TMCI always reported negative operating cash flow.
TMCI Yearly Net Income VS EBIT VS OCF VS FCFTMCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M -50M

1.2 Ratios

TMCI's Return On Assets of -25.49% is in line compared to the rest of the industry. TMCI outperforms 46.77% of its industry peers.
With a Return On Equity value of -56.18%, TMCI perfoms like the industry average, outperforming 48.92% of the companies in the same industry.
Industry RankSector Rank
ROA -25.49%
ROE -56.18%
ROIC N/A
ROA(3y)-24.09%
ROA(5y)-19.45%
ROE(3y)-52.01%
ROE(5y)-143.15%
ROIC(3y)N/A
ROIC(5y)N/A
TMCI Yearly ROA, ROE, ROICTMCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

With an excellent Gross Margin value of 79.87%, TMCI belongs to the best of the industry, outperforming 92.47% of the companies in the same industry.
In the last couple of years the Gross Margin of TMCI has remained more or less at the same level.
TMCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.08%
TMCI Yearly Profit, Operating, Gross MarginsTMCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

3

2. Health

2.1 Basic Checks

TMCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TMCI has been increased compared to 1 year ago.
The number of shares outstanding for TMCI has been increased compared to 5 years ago.
The debt/assets ratio for TMCI is higher compared to a year ago.
TMCI Yearly Shares OutstandingTMCI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
TMCI Yearly Total Debt VS Total AssetsTMCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of 0.06, we must say that TMCI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.06, TMCI perfoms like the industry average, outperforming 45.16% of the companies in the same industry.
TMCI has a Debt/Equity ratio of 0.62. This is a neutral value indicating TMCI is somewhat dependend on debt financing.
TMCI has a worse Debt to Equity ratio (0.62) than 63.98% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Altman-Z 0.06
ROIC/WACCN/A
WACC8.42%
TMCI Yearly LT Debt VS Equity VS FCFTMCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 3.37 indicates that TMCI has no problem at all paying its short term obligations.
TMCI has a Current ratio of 3.37. This is in the better half of the industry: TMCI outperforms 60.22% of its industry peers.
TMCI has a Quick Ratio of 2.36. This indicates that TMCI is financially healthy and has no problem in meeting its short term obligations.
TMCI's Quick ratio of 2.36 is in line compared to the rest of the industry. TMCI outperforms 59.14% of its industry peers.
Industry RankSector Rank
Current Ratio 3.37
Quick Ratio 2.36
TMCI Yearly Current Assets VS Current LiabilitesTMCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.89% over the past year.
Looking at the last year, TMCI shows a small growth in Revenue. The Revenue has grown by 7.90% in the last year.
The Revenue has been growing by 39.66% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)14.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4%
Revenue 1Y (TTM)7.9%
Revenue growth 3Y30.41%
Revenue growth 5Y39.66%
Sales Q2Q%11.37%

3.2 Future

Based on estimates for the next years, TMCI will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.19% on average per year.
The Revenue is expected to grow by 14.54% on average over the next years. This is quite good.
EPS Next Y4.7%
EPS Next 2Y-1%
EPS Next 3Y0.29%
EPS Next 5Y14.19%
Revenue Next Year1.99%
Revenue Next 2Y1.49%
Revenue Next 3Y3.57%
Revenue Next 5Y14.54%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TMCI Yearly Revenue VS EstimatesTMCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
TMCI Yearly EPS VS EstimatesTMCI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TMCI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TMCI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TMCI Price Earnings VS Forward Price EarningsTMCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TMCI Per share dataTMCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1%
EPS Next 3Y0.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TMCI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

TREACE MEDICAL CONCEPTS INC

NASDAQ:TMCI (12/29/2025, 8:22:15 PM)

After market: 2.49 +0.03 (+1.22%)

2.46

+0.04 (+1.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners61.26%
Inst Owner Change47.72%
Ins Owners20.77%
Ins Owner Change-0.45%
Market Cap156.75M
Revenue(TTM)218.88M
Net Income(TTM)-50.11M
Analysts50.91
Price Target5.44 (121.14%)
Short Float %7.83%
Short Ratio5.1
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.88%
Min EPS beat(2)4.79%
Max EPS beat(2)8.96%
EPS beat(4)4
Avg EPS beat(4)26.76%
Min EPS beat(4)4.79%
Max EPS beat(4)74.58%
EPS beat(8)7
Avg EPS beat(8)13.87%
EPS beat(12)10
Avg EPS beat(12)14.08%
EPS beat(16)12
Avg EPS beat(16)-130.3%
Revenue beat(2)0
Avg Revenue beat(2)-1.14%
Min Revenue beat(2)-1.26%
Max Revenue beat(2)-1.01%
Revenue beat(4)1
Avg Revenue beat(4)-0.75%
Min Revenue beat(4)-1.26%
Max Revenue beat(4)0.3%
Revenue beat(8)5
Avg Revenue beat(8)0.36%
Revenue beat(12)8
Avg Revenue beat(12)1.09%
Revenue beat(16)12
Avg Revenue beat(16)2.15%
PT rev (1m)-2.42%
PT rev (3m)-38.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2900%
EPS NY rev (1m)1.55%
EPS NY rev (3m)1.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-21.08%
Revenue NY rev (1m)-6.67%
Revenue NY rev (3m)-6.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.72
P/FCF N/A
P/OCF N/A
P/B 1.76
P/tB 2.27
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS3.44
BVpS1.4
TBVpS1.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.49%
ROE -56.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.87%
FCFM N/A
ROA(3y)-24.09%
ROA(5y)-19.45%
ROE(3y)-52.01%
ROE(5y)-143.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.08%
F-Score3
Asset Turnover1.11
Health
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 141.2%
Cap/Sales 6.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.37
Quick Ratio 2.36
Altman-Z 0.06
F-Score3
WACC8.42%
ROIC/WACCN/A
Cap/Depr(3y)349.5%
Cap/Depr(5y)305.94%
Cap/Sales(3y)7.38%
Cap/Sales(5y)5.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4%
EPS Next Y4.7%
EPS Next 2Y-1%
EPS Next 3Y0.29%
EPS Next 5Y14.19%
Revenue 1Y (TTM)7.9%
Revenue growth 3Y30.41%
Revenue growth 5Y39.66%
Sales Q2Q%11.37%
Revenue Next Year1.99%
Revenue Next 2Y1.49%
Revenue Next 3Y3.57%
Revenue Next 5Y14.54%
EBIT growth 1Y22.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year88.29%
EBIT Next 3Y24.32%
EBIT Next 5Y26.75%
FCF growth 1Y49.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y69.98%
OCF growth 3YN/A
OCF growth 5YN/A

TREACE MEDICAL CONCEPTS INC / TMCI FAQ

Can you provide the ChartMill fundamental rating for TREACE MEDICAL CONCEPTS INC?

ChartMill assigns a fundamental rating of 3 / 10 to TMCI.


Can you provide the valuation status for TREACE MEDICAL CONCEPTS INC?

ChartMill assigns a valuation rating of 0 / 10 to TREACE MEDICAL CONCEPTS INC (TMCI). This can be considered as Overvalued.


What is the profitability of TMCI stock?

TREACE MEDICAL CONCEPTS INC (TMCI) has a profitability rating of 2 / 10.


How financially healthy is TREACE MEDICAL CONCEPTS INC?

The financial health rating of TREACE MEDICAL CONCEPTS INC (TMCI) is 3 / 10.


Can you provide the expected EPS growth for TMCI stock?

The Earnings per Share (EPS) of TREACE MEDICAL CONCEPTS INC (TMCI) is expected to grow by 4.7% in the next year.